Insider Selling: Glaukos Co. (NYSE:GKOS) Insider Sells 3,416 Shares of Stock

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Stock Down 1.6 %

Shares of NYSE GKOS opened at $157.97 on Friday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $8.71 billion, a PE ratio of -52.31 and a beta of 1.04. The stock’s fifty day simple moving average is $153.00 and its two-hundred day simple moving average is $139.16. Glaukos Co. has a 12-month low of $83.90 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. As a group, analysts expect that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Institutional Trading of Glaukos

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier’s stock worth $895,887,000 after purchasing an additional 101,838 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. State Street Corp boosted its position in shares of Glaukos by 5.3% in the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after purchasing an additional 98,109 shares in the last quarter. Invesco Ltd. boosted its position in shares of Glaukos by 4.9% in the 4th quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier’s stock worth $218,708,000 after purchasing an additional 68,310 shares in the last quarter. Finally, Primecap Management Co. CA boosted its position in shares of Glaukos by 2.0% in the 3rd quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $140.00 to $200.00 in a report on Wednesday. Morgan Stanley downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Monday, December 2nd. Wells Fargo & Company raised their price objective on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Finally, BTIG Research raised their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $159.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.